Detalhe da pesquisa
1.
Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN.
J Eur Acad Dermatol Venereol
; 2024 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38752592
2.
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 186(3): 466-475, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34652810
3.
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
J Eur Acad Dermatol Venereol
; 36(12): 2393-2400, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-35920762
4.
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Br J Dermatol
; 184(1): 50-59, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32594522
5.
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Br J Dermatol
; 184(4): 640-651, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32531798
6.
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Br J Dermatol
; 184(4): 652-662, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32652544
7.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Br J Dermatol
; 184(6): 1047-1058, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32880909
8.
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Br J Dermatol
; 184(3): 437-449, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33000465
9.
Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact.
J Eur Acad Dermatol Venereol
; 35(2): 417-421, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32978847
10.
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
J Eur Acad Dermatol Venereol
; 35(12): 2398-2408, 2021 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-34192387
11.
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
J Eur Acad Dermatol Venereol
; 35(1): 135-142, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-32365251
12.
Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials.
Br J Dermatol
; 182(4): 880-888, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31276189
13.
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.
Br J Dermatol
; 182(1): 180-189, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30916381
14.
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Br J Dermatol
; 182(6): 1359-1368, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31487406
15.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Br J Dermatol
; 182(3): 605-617, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31218661
16.
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
Br J Dermatol
; 182(6): e186-e209, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32476149
17.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Br J Dermatol
; 182(6): 1348-1358, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31887225
18.
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Br J Dermatol
; 182(5): 1120-1135, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31407311
19.
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
Br J Dermatol
; 180(2): 306-314, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30328108
20.
Conjunctivitis in dupilumab clinical trials.
Br J Dermatol
; 181(3): 459-473, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30851191